Safety and Immunogenicity of Intranasal BPZE1 Vaccination in Healthy Adults

• Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) (NIH)
• Overall Status: Completed
• CT.gov ID: NCT03541499
• Collaborator: (none)
• Enrollment: 50
• Location: 1
• Arms: 4
• Actual Duration (Months): 18.7
• Patients Per Site Per Month: 2.7

Study Details

Study Description

Brief Summary

This is a randomized, partially blind, placebo controlled, clinical trial evaluating a single intranasal dose of BPZE1 in healthy adults. The study will evaluate a lyophilized formulation of the product, with the goal of testing for the optimal dose for subsequent clinical trials. Fifty healthy adults, 18-49 years of age will be randomized to one of the four following treatment groups in a 3:3:3:1 ratio: 10^{7 colony forming units (CFU) of BPZE1 administered by VaxINator device, 10}9 CFU of BPZE1 administered by VaxINator device, placebo administered by VaxINator device, 10^{9 CFU of BPZE1 administered by needleless tuberculin syringe. Study duration will be approximately 12 months with a subject participation duration of approximately 6 months. The primary objective of this study is to assess the safety and tolerability of a single intranasal dose of either 10}7 or 10^9 CFU of lyophilized BPZE1 vaccine.

Condition or Disease	Intervention/Treatment	Phase
Pertussis; Pertussis Immunisation	Biological: BPZE1; Other: Placebo	Phase 2

Detailed Description

This is a phase 2a, single center, randomized, partially blind, placebo controlled, clinical trial evaluating a single intranasal dose of either 10^{7 colony forming units (CFU) or 10}9 CFU of BPZE1 in healthy adults. The study will evaluate a lyophilized formulation of the product, with the goal of testing for the optimal dose for subsequent clinical trials. Fifty healthy adults, 18-49 years of age will be randomized to one of the four following treatment groups in a 3:3:3:1 ratio: 10^{7 CFU of BPZE1 administered by VaxINator device, 10}9 CFU of BPZE1 administered by VaxINator device, placebo administered by VaxINator device, 10^{9 CFU of BPZE1 administered by needleless tuberculin syringe. Study duration will be approximately 12 months with a subject participation duration of approximately 6 months. The primary objective of this study is to assess the safety and tolerability of a single intranasal dose of either 10}7 or 10^{9 CFU of lyophilized BPZE1 vaccine. The secondary objectives of this study are: 1) to assess the humoral immunogenicity of lyophilized BPZE1 vaccine at Day 15, Day 29 and Day 181 following receipt of one intranasal dose of 10}7 or 10^{9 CFU of BPZE1; 2) to assess mucosal immunogenicity of lyophilized BPZE1 vaccine at Day 29 and Day 181 following receipt of one intranasal dose of 10}7 or 10^{9 CFU of BPZE1; 3) to evaluate nasal clearance of BPZE1 by culture at Day 29 (and if still positive, at Day 46) following receipt of one intranasal dose of lyophilized BPZE1 vaccine of 10}7 or 10^9 CFU of BPZE1.

Study Design

• Study Type: Interventional
• Actual Enrollment: 50 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Prevention
• Official Title: A Phase 2A Partially-Blind Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of Live Attenuated, Intranasal B. Pertussis Vaccine (BPZE1) in Healthy Adults
• Actual Study Start Date: Oct 23, 2018
• Actual Primary Completion Date: May 15, 2020
• Actual Study Completion Date: May 15, 2020

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1 800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1, n=15	Biological: BPZE1; Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.
Experimental: Group 2 800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1, n=15	Biological: BPZE1; Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.
Placebo Comparator: Group 3 800 microliters of Placebo administered intranasally with the VaxINator device on Day 1, n=15	Other: Placebo; The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
Experimental: Group 4 800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1, n=5	Biological: BPZE1; Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of either 10^7 colony forming units (CFU) or 10^9 CFU.

Outcome Measures

Primary Outcome Measures

1. Number of Participants Experiencing Adverse Events of Special Interest (AESIs) [Day 1 through Day 29]

   AESIs included medically attended wheezing events given the route of study product administration and the nature of the study product.

2. Number of Participants Experiencing New Onset Chronic Medical Conditions (NOCMCs) [Day 1 through Day 181]

   NOCMCs are defined as new medical conditions, not present at the time of screening or enrollment, that require ongoing medical care and intervention.

3. Number of Participants Experiencing Serious Adverse Events (SAEs) [Day 1 through Day 181]

   An adverse event was considered serious if, in the view of either the site principal investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect, or, when, based upon appropriate medical judgment they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

4. Number of Participants Experiencing Solicited Local Reactogenicity Adverse Events (AEs) [Day 1 through Day 15]

   The solicited local reactogenicity events included runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore/irritated throat, cough, and shortness of breath/wheezing.

5. Number of Participants Experiencing Solicited Systemic Reactogenicity AEs [Day 1 through Day 15]

   The solicited systemic reactogenicity events included fever, feverishness, fatigue, malaise, myalgia, arthralgia, headache, and rash/hypersensitivity.

6. Number of Participants Experiencing Unsolicited Non-Serious AEs [Day 1 through Day 29]

   Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of vaccination through Day 29.

7. Number of Participants Experiencing Severe Solicited Local Reactogenicity Adverse Events [Day 1 through Day 15]

   Solicited local reactogenicity events include runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore/irritated throat, cough, and shortness of breath/wheezing. They were graded as grade 1 (mild), grade 2 (moderate), or grade 3 (severe). Severe local events were those that required medical care or caused significant discomfort that prevented daily activity, including sore/irritated throat preventing eating or drinking and cough preventing sleep. Severe epistaxis events were bleeding events that required a medical encounter. Severe stuffy nose/congestion events caused the participant to be unable to breathe through the nose or to seek medical care.

8. Number of Participants Experiencing Severe Solicited Systemic Reactogenicity AEs [Day 1 through Day 15]

   Solicited systemic reactogenicity events include fever, feverishness, fatigue, malaise, myalgia, arthralgia, headache, and rash/hypersensitivity. They were graded as grade 1 (mild), grade 2 (moderate), and grade 3 (severe). For all symptoms except rash and fever, an event was considered severe if it caused significant interference and prevented daily activity. Severe rash/hypersensitivity events were those that caused generalized urticaria, anaphylaxis, or angioedema or localized urticaria that required medical encounter. Severe fever was a temperature exceeding 38.9°C.

Secondary Outcome Measures

1. Geometric Mean Fold Rise From Screening of the Ratio of Filamentous Hemagglutinin-specific IgA (FHA-IgA) to Total IgA by Nasal Aspirate [Screening, Day 29, Day 181]

   Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FHA-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.

2. Geometric Mean Fold Rise From Screening of the Ratio of Fimbriae-Specific IgA (FIM-IgA) to Total IgA by Nasal Aspirate [Screening, Day 29, and Day 181]

   Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FIM-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.

3. Geometric Mean Fold Rise From Screening of the Ratio of Pertactin-Specific IgA (PRN-IgA) to Total IgA by Nasal Aspirate [Screening, Day 29, and Day 181]

   Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PRN-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.

4. Geometric Mean Fold Rise From Screening of the Ratio of Pertussis Toxin-Specific IgA (PT-IgA) to Total IgA by Nasal Aspirate [Screening, Day 29, and Day 181]

   Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PT-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.

5. Geometric Mean Fold Rise From Baseline Serum IgA and Serum IgG ELISA Titers to Filamentous Hemagglutinin (FHA) [Day 1, Day 15, Day 29, and Day 181]

   Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen. The fold rise in FHA-IgA from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.

6. Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Fimbriae 2/3 (FIM) [Day 1, Day 15, Day 29, and Day 181]

   Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen. The fold rise in FIM-IgA and FIM-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.

7. Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Pertactin (PRN) [Day 1, Day 15, Day 29, and Day 181]

   Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen. The fold rise in PRN-IgA and PRN-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.

8. Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Pertussis Toxin (PT) [Day 1, Day 15, Day 29, and Day 181]

   Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) pertussis antigen. The fold rise in PT-IgA and PT-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.

9. Geometric Mean Titer by Serum IgA and Serum IgG to Fimbriae 2/3 [Day 1, Day 15, Day 29, and Day 181]

   Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. The geometric mean FIM-IgA titer and FIM-IgG titer were calculated for each study arm.

10. Geometric Mean Titer by Serum IgA and Serum IgG to Pertactin [Day 1, Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen via a bead-based assay. The geometric mean PRN-IgA titer and PRN-IgG titer were calculated for each study arm.

11. Geometric Mean Titer by Serum IgA and Serum IgG to Pertussis Toxin [Day 1, Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) pertussis antigen via a bead-based assay. The geometric mean PT-IgA titer and PT-IgG titer were calculated for each study arm.

12. Percentage of Participants Achieving Seroconversion to One or More Pertussis Antigens as Measured by Serum IgA or Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 pertussis antigens. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA or antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to at least one pertussis antigen at each and across immunogenicity timepoints (Day 15, Day 29, and Day 181) was calculated.

13. Percentage of Participants Achieving Seroconversion to Two or More Pertussis Antigens as Measured by Serum IgA or Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 pertussis antigens. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA levels or antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to at least two pertussis antigens at each and across all immunogenicity timepoints (Day 15, Day 29, and Day 181) was calculated.

14. Percentage of Participants Achieving Seroconversion to One or More Pertussis Antigens as Measured by the Ratio of Antigen-Specific Mucosal IgA Levels to Total Mucosal IgA Levels [Day 29 and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis vaccine antigens via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted to at least one pertussis antigen at each and any immunogenicity timepoint was calculated.

15. Percentage of Participants With Detectable B. Pertussis From Nasopharyngeal Cultures [Day 29 and Day 46]

    Colonization of live B. pertussis organism was assessed from a nasopharyngeal swab performed 28 days after vaccine administration (Day 29) to ensure all participants were cleared of colonization. Standard microbiologic techniques were used to assess the presence of B. pertussis by culture. If any participants were positive for B. pertussis culture at Day 29, they were asked to return at Day 46 for a repeat culture. If the participant was not positive for B. pertussis at Day 29, no subsequent nasopharyngeal samples for culture were collected.

16. Percentage of Participants Achieving Seroconversion to Filamentous Hemagglutinin as Measured by Serum IgA and Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA levels and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA and IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to FHA-IgA and FHA-IgG at any and each immunogenicity timepoint (Day 15, Day 29, and Day 181) was calculated.

17. Percentage of Participants Achieving Seroconversion to Fimbriae 2/3 as Measured by Serum IgA and Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA levels and IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to FIM-IgA or FIM-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or and Day 181) was calculated.

18. Geometric Mean Titer Ratio of Mucosal FHA-IgA to Total IgA by Nasal Aspirate [Screening, Day 29, Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FHA-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.

19. Geometric Mean Titer Ratio of Mucosal FIM-IgA to Total IgA by Nasal Aspirate [Screening, Day 29, Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FIM-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.

20. Geometric Mean Titer Ratio of Mucosal PRN-IgA to Total IgA by Nasal Aspirate [Screening, Day 29, Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PRN-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.

21. Geometric Mean Titer Ratio of Mucosal PT-IgA to Total IgA by Nasal Aspirate [Screening, Day 29, and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PT-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.

22. Geometric Mean Titer by Serum IgA and Serum IgG to Filamentous Hemagglutinin [Day 1, Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. The geometric mean FHA-IgA titer and FHA-IgG titer were calculated for each study arm.

23. Percentage of Participants Achieving Seroconversion to Pertactin as Measured by Serum IgA and Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA and antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to PRN-IgA and PRN-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or Day 181) were calculated.

24. Percentage of Participants Achieving Seroconversion to Pertussis Toxin as Measured by Serum IgA and Serum IgG Levels [Day 15, Day 29, and Day 181]

    Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA/IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to PT-IgA and PT-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or and Day 181) was calculated.

25. Percentage of Participants Achieving Seroconversion to Filamentous Hemagglutinin as Measured by Mucosal IgA Levels [Day 29 and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted FHA-IgA at each and any immunogenicity timepoint (Day 29 or Day 181) was calculated.

26. Percentage of Participants Achieving Seroconversion to Fimbriae 2/3 as Measured by Mucosal IgA Levels [Day 29 and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted FIM-IgA at each and any immunogenicity timepoint (Day 29 and Day 181) was calculated.

27. Percentage of Participants Achieving Seroconversion to Pertactin as Measured by Mucosal IgA Levels [Day 29 and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted PRN-IgA at each and any immunogenicity timepoint (Day 29 and Day 181) was calculated.

28. Percentage of Participants Achieving Seroconversion to Pertussis Toxin as Measured by Mucosal IgA Levels [Day 29 and Day 181]

    Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was calculated for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted PT-IgA at each immunogenicity timepoint (Day 29 and Day 181) was calculated.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 49 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

Subjects eligible to participate in this study must meet all inclusion criteria:

1. Provide written informed consent prior to initiation of any study procedures.

2. Able to understand and comply with planned study procedures and be available for all study visits.

3. Males or non-pregnant females, 18-49 years of age, inclusive.

4. In good health*.

*As determined by medical history and physical examination to evaluate acute or currently ongoing chronic medical diagnoses or conditions, defined as those that have been present for at least 90 days that would affect the assessment of the safety of subjects or the immunogenicity of study vaccinations. Chronic medical diagnoses or conditions should be stable for the last 60 days. This includes no change in chronic prescription medication, dose, or frequency because of deterioration of the chronic medical diagnosis or condition in the 60 days prior to enrollment. Any prescription change that is due to change of health care provider, insurance company, etc., or that is done for financial reasons, if it is in the same class of medication, will not be considered a deviation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a deviation of this inclusion criterion. Subjects may be on chronic or as needed (prn) medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity and do not indicate a worsening of medical diagnosis or condition. Similarly, medication changes after enrollment and study vaccination are acceptable provided there was no deterioration in the subject's chronic medical condition that necessitated a medication change, and there is no additional risk to the subject or interference with the evaluation of responses to study vaccination. Note: Topical and inhaled medications (with the exception of inhaled or nasal corticosteroids within 30 days prior to enrollment), herbals, vitamins, and supplements are permitted.

1. Oral temperature is < / = 100 degrees Fahrenheit.

2. Pulse is 45 to 100 bpm, inclusive*. *Pulse can be 45 to 50 bpm, inclusive, if no other symptoms are present. Otherwise, pulse should be 50-100 bpm.

3. Systolic blood pressure is 85 to 150 mm Hg, inclusive.

4. Diastolic blood pressure is 55 to 95 mm Hg, inclusive.

5. White blood cell count is 3,900 cells/microliter or greater*.

*Abnormalities in white blood count, hemoglobin, platelet count, alanine aminotransferase, and serum creatinine that are suspected to be due to laboratory anomalies may be repeated once to ensure accuracy; additionally, otherwise eligible subjects with grade 1 abnormalities in these values may be considered for enrollment if, in the opinion of the investigator (or clinician on the 1572), the abnormalities are not clinically significant and do not pose additional risk to the study or the volunteer.

1. Hemoglobin is 13.0 g/dL or greater (men) or 11.8 g/dL or greater (women)*. *Abnormalities in white blood count, hemoglobin, platelet count, alanine aminotransferase, and serum creatinine that are suspected to be due to laboratory anomalies may be repeated once to ensure accuracy; additionally, otherwise eligible subjects with grade 1 abnormalities in these values may be considered for enrollment if, in the opinion of the investigator (or clinician on the 1572), the abnormalities are not clinically significant and do not pose additional risk to the study or the volunteer.

2. Platelet count is 135,000 cells/microliter or greater*.

*Abnormalities in white blood count, hemoglobin, platelet count, alanine aminotransferase, and serum creatinine that are suspected to be due to laboratory anomalies may be repeated once to ensure accuracy; additionally, otherwise eligible subjects with grade 1 abnormalities in these values may be considered for enrollment if, in the opinion of the investigator (or clinician on the 1572), the abnormalities are not clinically significant and do not pose additional risk to the study or the volunteer.

1. Alanine aminotransferase is < 45 U/L (women) or 62 U/L (men)*.

*Abnormalities in white blood count, hemoglobin, platelet count, alanine aminotransferase, and serum creatinine that are suspected to be due to laboratory anomalies may be repeated once to ensure accuracy; additionally, otherwise eligible subjects with grade 1 abnormalities in these values may be considered for enrollment if, in the opinion of the investigator (or clinician on the 1572), the abnormalities are not clinically significant and do not pose additional risk to the study or the volunteer.

1. Serum creatinine is < / = 1.25 mg/dL (men) or 1.11 mg/dL (women)*.

*Abnormalities in white blood count, hemoglobin, platelet count, alanine aminotransferase, and serum creatinine that are suspected to be due to laboratory anomalies may be repeated once to ensure accuracy; additionally, otherwise eligible subjects with grade 1 abnormalities in these values may be considered for enrollment if, in the opinion of the investigator (or clinician on the 1572), the abnormalities are not clinically significant and do not pose additional risk to the study or the volunteer.

1. Negative serum HIV antibody assay.

2. Women of childbearing potential* must use an acceptable contraception method** from 30 days before study vaccination until 60 days after vaccination.

*Not sterilized via tubal ligation, bilateral oophorectomy, salpingectomy, hysterectomy, or successful Essure(R) placement (permanent, non-surgical, non-hormonal sterilization) with documented radiological confirmation test at least 90 days after the procedure, and still menstruating or < 1 year has passed since the last menses if menopausal.

• Includes non-male sexual relationships, abstinence from sexual intercourse with a male partner, monogamous relationship with vasectomized partner who has been vasectomized for 180 days or more prior to the subject receiving study vaccination, barrier methods such as condoms or diaphragms/cervical caps with spermicide, effective intrauterine devices, NuvaRing(R), and licensed hormonal methods such as implants, injectables or oral contraceptives ("the pill").

1. Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to study vaccination.

Exclusion Criteria:

1. Have immunosuppression as a result of an underlying illness or treatment, or use of anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to study vaccination.

2. Have known or suspected active chronic autoinflammatory condition.

3. Have known active neoplastic disease (excluding non-melanoma skin cancer) or a history of any hematologic malignancy.

4. Have a history of persistent asthma, major anatomic nasopharyngeal abnormality, or sinus polyp disease due to chronic sinusitis*.

*If a patient has a history of nasopharyngeal surgery such as, but not limited to rhinoplasty, tonsillectomy or sinus surgery, adequate healing time per the judgement of the investigator must occur prior to enrollment.

1. Have known hepatitis B or hepatitis C infection.

2. Have a history of alcohol or drug abuse within 5 years prior to study vaccination.

3. Currently untreated or clinically unstable (in the opinion of the investigator) schizophrenia, bipolar disease, or other psychiatric diagnosis that may interfere with subject compliance or safety evaluations.

4. Have been hospitalized for psychiatric illness, history of suicide attempt, or confinement for danger to self or others within 5 years prior to study vaccination.

5. Have received corticosteroids (including oral, parenteral, inhaled, nasal, or intra-articular) of any dose within 30 days prior to study vaccination.

6. Individual with PT serum IgG antibodies > / = 20 IU/mL and / or PRN serum IgG antibodies > / = 125 IU/ml.

7. Unwilling to refrain from smoking tobacco for 28 days post vaccination.

8. Receipt of immunoglobulin or blood derived products within 90 days of enrollment.

9. Receipt of a vaccine against pertussis in the past 2 years.

10. Receipt of a live vaccine within 30 days of study vaccination or an inactivated vaccine within 14 days of study vaccination.

11. Planned vaccination with a licensed vaccine within 28 days of study vaccination.

12. History of severe allergic reaction (e.g., anaphylaxis) or Bell's palsy, or Guillain-Barre syndrome, after a previous dose of any diphtheria toxoid-tetanus toxoid-, or pertussis-containing vaccine, or encephalopathy within 7 days of administration of a previous pertussis containing vaccine.

13. History of a progressive neurologic disorder.

14. In close contact* with children less than 1 year of age or contact with persons with known immunocompromising conditions.

*Close contact includes sharing a household, serving as a healthcare worker, or working professionally in settings with repeated exposures.

1. Receipt of B. pertussis-active antibiotics* within 7 days prior to vaccination.

*B. pertussis active antibiotics include macrolides, fluoroquinolones, trimethoprim-sulfamethoxazole, tetracyclines.

1. Known hypersensitivity to any component of the study vaccine.

2. Hypersensitivity to azithromycin, which may be used in the event of ongoing BPZE1 colonization.

3. Any condition that, in the opinion of the investigator, might interfere with objectives of the study or safety to the individual.

4. Acute illness, including temperature > 100 degrees Fahrenheit within one week prior to vaccination*.

• Enrollment may be postponed if acute illness occurs; subjects must remain within the screening window, however, and must be rescreened if > 30 days elapses prior to enrollment.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Vanderbilt University - Pediatric - Vanderbilt Vaccine Research Center	Nashville	Tennessee	United States	37232-2573

Sponsors and Collaborators

• National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

None specified.

Study Documents (Full-Text)

• Study Protocol - Jun 25, 2019
• Statistical Analysis Plan - Oct 29, 2019

More Information

Publications

None provided.

• Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)
• ClinicalTrials.gov Identifier: NCT03541499
• Other Study ID Numbers: 17-0010; HHSN272201300023I
• First Posted: May 30, 2018
• Last Update Posted: Feb 3, 2022
• Last Verified: Aug 18, 2021

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID): B. pertussis Vaccine; BPZE1; Immunogenicity; Safety
• Additional relevant MeSH terms: Whooping Cough

Study Results

Participant Flow

Recruitment Details	The study population includes 50 healthy adults,18-49 years of age, inclusive, who meet all eligibility criteria. Participants were enrolled between 01NOV2018 and 06DEC2019.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of B. pertussis vaccine (BPZE1) administered intranasally with the VaxINator device on Day 1. BPZE1: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of 10^7 colony forming units (CFU).	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1. BPZE1: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of 10^9 colony forming units (CFU).	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1. BPZE1: Lyophilized, live-attenuated Bordetella pertussis vaccine reconstituted with sterile water for injection (SWFI) and administered as a single intranasal dose of 10^9 colony forming units (CFU) .	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1. Placebo: The placebo consists of the same constituents in the same quantities as the BPZE1 investigational vaccines, absent the attenuated B. pertussis cells, reconstituted with sterile water for injection (SWFI).
Period Title: Overall Study
STARTED	15	15	5	15
COMPLETED	15	15	5	15
NOT COMPLETED	0	0	0	0

Baseline Characteristics

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator	Total
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.	Total of all reporting groups
Overall Participants	15	15	5	15	50
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	30.3 (10.7)	29.1 (8.8)	30.2 (8.9)	30.9 (9.5)	30.1 (9.3)
Sex: Female, Male (Count of Participants)
Female	9 60%	9 60%	2 40%	11 73.3%	31 62%
Male	6 40%	6 40%	3 60%	4 26.7%	19 38%
Ethnicity (NIH/OMB) (Count of Participants)
Hispanic or Latino	0 0%	0 0%	0 0%	1 6.7%	1 2%
Not Hispanic or Latino	15 100%	15 100%	5 100%	14 93.3%	49 98%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 0%	0 0%
Asian	5 33.3%	1 6.7%	0 0%	2 13.3%	8 16%
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 0%	0 0%
Black or African American	0 0%	0 0%	0 0%	0 0%	0 0%
White	10 66.7%	14 93.3%	5 100%	13 86.7%	42 84%
More than one race	0 0%	0 0%	0 0%	0 0%	0 0%
Unknown or Not Reported	0 0%	0 0%	0 0%	0 0%	0 0%

Outcome Measures

1. Primary Outcome

Title	Number of Participants Experiencing Adverse Events of Special Interest (AESIs)
Description	AESIs included medically attended wheezing events given the route of study product administration and the nature of the study product.
Time Frame	Day 1 through Day 29

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Count of Participants [Participants]	0 0%	0 0%	0 0%	0 0%

2. Primary Outcome

Title	Number of Participants Experiencing New Onset Chronic Medical Conditions (NOCMCs)
Description	NOCMCs are defined as new medical conditions, not present at the time of screening or enrollment, that require ongoing medical care and intervention.
Time Frame	Day 1 through Day 181

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Count of Participants [Participants]	1 6.7%	0 0%	0 0%	0 0%

3. Primary Outcome

Title	Number of Participants Experiencing Serious Adverse Events (SAEs)
Description	An adverse event was considered serious if, in the view of either the site principal investigator or sponsor, it resulted in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect, or, when, based upon appropriate medical judgment they may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.
Time Frame	Day 1 through Day 181

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Count of Participants [Participants]	0 0%	0 0%	0 0%	0 0%

4. Primary Outcome

Title	Number of Participants Experiencing Solicited Local Reactogenicity Adverse Events (AEs)
Description	The solicited local reactogenicity events included runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore/irritated throat, cough, and shortness of breath/wheezing.
Time Frame	Day 1 through Day 15

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Runny nose	6 40%	7 46.7%	2 40%	5 33.3%
Stuffy nose/congestion	8 53.3%	8 53.3%	2 40%	6 40%
Nasal pain/irritation	1 6.7%	1 6.7%	0 0%	0 0%
Epistaxis	1 6.7%	0 0%	0 0%	1 6.7%
Sneezing	4 26.7%	5 33.3%	1 20%	3 20%
Sinus pressure/pain	1 6.7%	4 26.7%	0 0%	2 13.3%
Sore/irritated throat	4 26.7%	4 26.7%	2 40%	3 20%
Cough	6 40%	2 13.3%	2 40%	2 13.3%
Shortness of breath/wheezing	2 13.3%	1 6.7%	0 0%	0 0%

5. Primary Outcome

Title	Number of Participants Experiencing Solicited Systemic Reactogenicity AEs
Description	The solicited systemic reactogenicity events included fever, feverishness, fatigue, malaise, myalgia, arthralgia, headache, and rash/hypersensitivity.
Time Frame	Day 1 through Day 15

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Fever	1 6.7%	0 0%	0 0%	0 0%
Feverishness	1 6.7%	2 13.3%	0 0%	1 6.7%
Fatigue (tiredness)	4 26.7%	4 26.7%	2 40%	5 33.3%
Malaise (general unwell feeling)	3 20%	3 20%	1 20%	2 13.3%
Myalgia (body aches/muscular pain)	0 0%	2 13.3%	1 20%	1 6.7%
Arthralgia (joint pain)	0 0%	3 20%	1 20%	1 6.7%
Headache	5 33.3%	9 60%	2 40%	8 53.3%
Rash/hypersensitivity	1 6.7%	0 0%	0 0%	0 0%

6. Primary Outcome

Title	Number of Participants Experiencing Unsolicited Non-Serious AEs
Description	Adverse events were defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product regardless of its causal relationship to the study treatment. Unsolicited non-serious AEs were documented and reported from the time of vaccination through Day 29.
Time Frame	Day 1 through Day 29

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Count of Participants [Participants]	3 20%	3 20%	1 20%	5 33.3%

7. Primary Outcome

Title	Number of Participants Experiencing Severe Solicited Local Reactogenicity Adverse Events
Description	Solicited local reactogenicity events include runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore/irritated throat, cough, and shortness of breath/wheezing. They were graded as grade 1 (mild), grade 2 (moderate), or grade 3 (severe). Severe local events were those that required medical care or caused significant discomfort that prevented daily activity, including sore/irritated throat preventing eating or drinking and cough preventing sleep. Severe epistaxis events were bleeding events that required a medical encounter. Severe stuffy nose/congestion events caused the participant to be unable to breathe through the nose or to seek medical care.
Time Frame	Day 1 through Day 15

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Runny nose	0 0%	0 0%	0 0%	0 0%
Stuffy nose/congestion	0 0%	0 0%	0 0%	0 0%
Nasal pain/irritation	0 0%	0 0%	0 0%	0 0%
Epistaxis	0 0%	0 0%	0 0%	0 0%
Sneezing	0 0%	0 0%	0 0%	0 0%
Sinus pressure/pain	0 0%	0 0%	0 0%	0 0%
Sore/irritated throat	0 0%	0 0%	0 0%	0 0%
Cough	0 0%	0 0%	0 0%	0 0%
Shortness of breath/wheezing	0 0%	0 0%	0 0%	0 0%

8. Secondary Outcome

Title	Geometric Mean Fold Rise From Screening of the Ratio of Filamentous Hemagglutinin-specific IgA (FHA-IgA) to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FHA-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Day 29	1.2	1.7	0.3	1
Day 181	0.8	2	0.4	1.2

9. Secondary Outcome

Title	Geometric Mean Fold Rise From Screening of the Ratio of Fimbriae-Specific IgA (FIM-IgA) to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FIM-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Day 29	1.7	6.2	0.7	0.6
Day 181	1.1	6.7	1	0.8

10. Secondary Outcome

Title	Geometric Mean Fold Rise From Screening of the Ratio of Pertactin-Specific IgA (PRN-IgA) to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PRN-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Day 29	1.1	3.3	1.3	0.8
Day 181	1.1	3.5	3.3	1

11. Secondary Outcome

Title	Geometric Mean Fold Rise From Screening of the Ratio of Pertussis Toxin-Specific IgA (PT-IgA) to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PT-IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. The geometric mean fold rise of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Day 29	0.9	1.4	0.9	2.2
Day 181	1.3	1.6	1.6	1.2

12. Secondary Outcome

Title	Geometric Mean Fold Rise From Baseline Serum IgA and Serum IgG ELISA Titers to Filamentous Hemagglutinin (FHA)
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen. The fold rise in FHA-IgA from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 15	0.8	1.3	1.4	1
IgA - Day 29	1.4	2.5	3	0.8
IgA - Day 181	1.2	2.1	2.3	1.1
IgG - Day 15	1	1.2	0.8	1.1
IgG - Day 29	1.7	1.5	1.3	0.9
IgG - Day 181	1.8	1.7	1.2	1

13. Secondary Outcome

Title	Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Fimbriae 2/3 (FIM)
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen. The fold rise in FIM-IgA and FIM-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 15	1	1.1	1.1	1
IgA - Day 29	2.1	2.2	3.2	0.7
IgA - Day 181	1.4	2	2.3	1.1
IgG - Day 15	1.1	1.5	1	1
IgG - Day 29	1.6	2.6	1.2	1
IgG - Day 181	1.2	2.8	1.2	0.9

14. Secondary Outcome

Title	Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Pertactin (PRN)
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen. The fold rise in PRN-IgA and PRN-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who have received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 15	0.7	1.6	1.1	1.1
IgA - Day 29	0.9	3.2	2.2	1.1
IgA - Day 181	0.9	3.2	1.5	1.3
IgG - Day 15	1	1.5	0.9	1.1
IgG - Day 29	1.7	2.3	1.2	0.9
IgG - Day 181	1.5	2.5	0.9	0.9

15. Secondary Outcome

Title	Geometric Mean Fold Rise From Baseline of Serum IgA and Serum IgG ELISA Titers to Pertussis Toxin (PT)
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to perform a bead-based assay to measure serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) pertussis antigen. The fold rise in PT-IgA and PT-IgG from baseline was calculated for each participant and the geometric mean of the fold rise was calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who have received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 15	1.3	1.9	1	1
IgA - Day 29	1.4	1.9	1.4	1.2
IgA - Day 181	1	1.8	1	1.4
IgG - Day 15	1.1	1.2	0.7	1
IgG - Day 29	1.5	1.4	1.5	1
IgG - Day 181	1.9	1.4	1.1	0.9

16. Secondary Outcome

Title	Geometric Mean Titer by Serum IgA and Serum IgG to Fimbriae 2/3
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. The geometric mean FIM-IgA titer and FIM-IgG titer were calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 1	3.40	3.94	1.85	2.68
IgA - Day 15	3.27	4.26	2.04	2.68
IgA - Day 29	7.07	8.84	5.92	1.79
IgA - Day 181	5.30	8.01	4.29	2.69
IgG - Day 1	51.71	15.98	129.14	24.48
IgG - Day 15	56.73	24.17	129.80	25.30
IgG - Day 29	84.12	41.30	160.50	24.35
IgG - Day 181	80.27	45.32	159.90	21.84

17. Secondary Outcome

Title	Geometric Mean Titer by Serum IgA and Serum IgG to Pertactin
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen via a bead-based assay. The geometric mean PRN-IgA titer and PRN-IgG titer were calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 1	10.53	3.82	3.57	2.88
IgA - Day 15	7.69	6.21	4.07	3.22
IgA - Day 29	9.32	12.38	8.02	3.19
IgA - Day 181	7.90	12.19	5.43	4.10
IgG - Day 1	38.69	17.68	48.47	8.81
IgG - Day 15	38.59	26.42	41.42	9.58
IgG - Day 29	65.11	41.07	58.20	7.63
IgG - Day 181	53.49	44.92	42.76	11.36

18. Secondary Outcome

Title	Geometric Mean Titer by Serum IgA and Serum IgG to Pertussis Toxin
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA levels and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) pertussis antigen via a bead-based assay. The geometric mean PT-IgA titer and PT-IgG titer were calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 1	0.66	0.48	0.91	0.82
IgA - Day 15	0.86	0.92	0.88	0.80
IgA - Day 29	0.91	0.95	1.29	0.99
IgA - Day 181	0.82	0.86	0.91	1.28
IgG - Day 1	3.36	4.00	10.10	3.41
IgG - Day 15	3.65	4.77	7.36	3.38
IgG - Day 29	5.20	5.41	15.01	3.42
IgG - Day 181	6.39	5.67	10.86	3.09

19. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to One or More Pertussis Antigens as Measured by Serum IgA or Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 pertussis antigens. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA or antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to at least one pertussis antigen at each and across immunogenicity timepoints (Day 15, Day 29, and Day 181) was calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	67 446.7%	100 666.7%	60 1200%	73 486.7%
Day 15	33 220%	67 446.7%	60 1200%	40 266.7%
Day 29	53 353.3%	93 620%	60 1200%	47 313.3%
Day 181	42 280%	93 620%	60 1200%	57 380%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	At any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.807
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	At any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.043
	Comments
	Method	Barnard's exact test
	Comments

20. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Two or More Pertussis Antigens as Measured by Serum IgA or Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae 2/3 pertussis antigens. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA levels or antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to at least two pertussis antigens at each and across all immunogenicity timepoints (Day 15, Day 29, and Day 181) was calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	53 353.3%	73 486.7%	60 1200%	53 353.3%
Day 15	7 46.7%	53 353.3%	20 400%	27 180%
Day 29	27 180%	73 486.7%	60 1200%	20 133.3%
Day 181	25 166.7%	67 446.7%	60 1200%	36 240%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	1.000
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.301
	Comments
	Method	Barnard's exact test
	Comments

21. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to One or More Pertussis Antigens as Measured by the Ratio of Antigen-Specific Mucosal IgA Levels to Total Mucosal IgA Levels
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis vaccine antigens via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted to at least one pertussis antigen at each and any immunogenicity timepoint was calculated.
Time Frame	Day 29 and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	60 400%	93 620%	80 1600%	80 533.3%
Day 29	53 353.3%	73 486.7%	60 1200%	73 486.7%
Day 181	50 333.3%	93 620%	80 1600%	50 333.3%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	1.000
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.009
	Comments
	Method	Barnard's exact test
	Comments

22. Secondary Outcome

Title	Percentage of Participants With Detectable B. Pertussis From Nasopharyngeal Cultures
Description	Colonization of live B. pertussis organism was assessed from a nasopharyngeal swab performed 28 days after vaccine administration (Day 29) to ensure all participants were cleared of colonization. Standard microbiologic techniques were used to assess the presence of B. pertussis by culture. If any participants were positive for B. pertussis culture at Day 29, they were asked to return at Day 46 for a repeat culture. If the participant was not positive for B. pertussis at Day 29, no subsequent nasopharyngeal samples for culture were collected.
Time Frame	Day 29 and Day 46

Outcome Measure Data

Analysis Population Description

The Per Protocol (PP) Population includes all participants in the immunogenicity population, excluding participants ineligible at baseline. Data is excluded from PP analyses from visits after major protocol deviations and study visits that occurred greater than 3 days out of window. Data from 1 participant was excluded from the BPZE1 10^7 CFU by VaxINator group due to receipt of immunosuppressive therapy within 30 days of study vaccination.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	14	15	5	15
Day 29	0 0%	0 0%	0 0%	0 0%

23. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Filamentous Hemagglutinin as Measured by Serum IgA and Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA levels and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA and IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to FHA-IgA and FHA-IgG at any and each immunogenicity timepoint (Day 15, Day 29, and Day 181) was calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Any Time Point	20 133.3%	67 446.7%	60 1200%	33 220%
IgA - Day 15	13 86.7%	20 133.3%	40 800%	7 46.7%
IgA - Day 29	13 86.7%	67 446.7%	60 1200%	7 46.7%
IgA - Day 181	17 113.3%	40 266.7%	60 1200%	21 140%
IgG - Any Time Point	47 313.3%	53 353.3%	40 800%	13 86.7%
IgG - Day 15	7 46.7%	7 46.7%	0 0%	7 46.7%
IgG - Day 29	33 220%	40 266.7%	40 800%	0 0%
IgG - Day 181	33 220%	47 313.3%	20 400%	7 46.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.526
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.100
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.055
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments
	Method	Barnard's exact test
	Comments

24. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Fimbriae 2/3 as Measured by Serum IgA and Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to fimbriae 2/3 (FIM) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA levels and IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to FIM-IgA or FIM-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or and Day 181) was calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Any Time Point	27 180%	53 353.3%	60 1200%	7 46.7%
IgA - Day 15	0 0%	13 86.7%	0 0%	0 0%
IgA - Day 29	27 180%	53 353.3%	60 1200%	0 0%
IgA - Day 181	8 53.3%	40 266.7%	40 800%	7 46.7%
IgG - Any Time Point	20 133.3%	53 353.3%	0 0%	13 86.7%
IgG - Day 15	0 0%	20 133.3%	0 0%	13 86.7%
IgG - Day 29	20 133.3%	53 353.3%	0 0%	0 0%
IgG - Day 181	17 113.3%	47 313.3%	0 0%	7 46.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.174
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.006
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.745
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments
	Method	Barnard's exact test
	Comments

25. Secondary Outcome

Title	Geometric Mean Titer Ratio of Mucosal FHA-IgA to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FHA-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Screening	0.0154	0.0133	0.0251	0.0147
Day 29	0.0178	0.0229	0.0069	0.0154
Day 181	0.011	0.0263	0.0109	0.0185

26. Secondary Outcome

Title	Geometric Mean Titer Ratio of Mucosal FIM-IgA to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of FIM-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Screening	0.0023	0.0012	0.0073	0.0023
Day 29	0.0039	0.0073	0.0052	0.0015
Day 181	0.0021	0.0078	0.0074	0.0017

27. Secondary Outcome

Title	Geometric Mean Titer Ratio of Mucosal PRN-IgA to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PRN-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Screening	0.0167	0.007	0.0063	0.0106
Day 29	0.0186	0.0231	0.0083	0.0087
Day 181	0.0157	0.0244	0.0207	0.0102

28. Secondary Outcome

Title	Geometric Mean Titer Ratio of Mucosal PT-IgA to Total IgA by Nasal Aspirate
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The ratio of PT-IgA to total mucosal IgA was computed for each participant and the geometric mean of the ratio was calculated for each study arm.
Time Frame	Screening, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who have received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Screening	0.0014	0.0011	0.0021	0.0011
Day 29	0.0013	0.0015	0.0018	0.0024
Day 181	0.0016	0.0017	0.0033	0.0013

29. Secondary Outcome

Title	Geometric Mean Titer by Serum IgA and Serum IgG to Filamentous Hemagglutinin
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure serum IgA and serum IgG levels (in ELISA units/mL) to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. The geometric mean FHA-IgA titer and FHA-IgG titer were calculated for each study arm.
Time Frame	Day 1, Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Day 1	3.83	3.54	1.21	2.71
IgA - Day 15	3.06	4.66	1.75	2.62
IgA - Day 29	5.27	8.67	3.68	2.21
IgA - Day 181	5.13	7.52	2.81	3.3
IgG - Day 1	19.59	19.65	16.59	12.81
IgG - Day 15	19.99	23.19	12.78	14.14
IgG - Day 29	33.49	29.4	20.9	11.96
IgG - Day 181	32.73	32.92	19.62	13.84

30. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Pertactin as Measured by Serum IgA and Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertactin (PRN) pertussis antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA and antigen-specific IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to PRN-IgA and PRN-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or Day 181) were calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Any Time Point	13 86.7%	80 533.3%	40 800%	53 353.3%
IgA - Day 15	0 0%	40 266.7%	20 400%	13 86.7%
IgA - Day 29	13 86.7%	67 446.7%	40 800%	20 133.3%
IgA - Day 181	17 113.3%	67 446.7%	40 800%	36 240%
IgG - Any Time Point	33 220%	47 313.3%	40 800%	20 133.3%
IgG - Day 15	7 46.7%	33 220%	0 0%	13 86.7%
IgG - Day 29	27 180%	40 266.7%	40 800%	7 46.7%
IgG - Day 181	25 166.7%	47 313.3%	0 0%	7 46.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.023
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.142
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.526
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.142
	Comments
	Method	Barnard's exact test
	Comments

31. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Pertussis Toxin as Measured by Serum IgA and Serum IgG Levels
Description	Approximately 10 mL of venous blood was collected from participants immediately prior to the first study vaccination on Day 1 (baseline), Day 15, Day 29, and Day 181 to measure via a bead-based assay serum IgA and serum IgG levels (in ELISA units/mL) to pertussis toxin (PT) antigen. Seroconversion was defined as at least a 2-fold rise in antigen-specific IgA/IgG levels post-baseline compared to baseline levels. The percentage of participants who seroconverted to PT-IgA and PT-IgG at any and each immunogenicity timepoint (Day 15, Day 29, or and Day 181) was calculated.
Time Frame	Day 15, Day 29, and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
IgA - Any Time Point	53 353.3%	60 400%	20 400%	60 400%
IgA - Day 15	13 86.7%	47 313.3%	20 400%	33 220%
IgA - Day 29	33 220%	47 313.3%	20 400%	33 220%
IgA - Day 181	17 113.3%	47 313.3%	20 400%	50 333.3%
IgG - Any Time Point	27 180%	40 266.7%	20 400%	13 86.7%
IgG - Day 15	13 86.7%	13 86.7%	0 0%	7 46.7%
IgG - Day 29	13 86.7%	33 220%	20 400%	7 46.7%
IgG - Day 181	25 166.7%	20 133.3%	20 400%	0 0%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.836
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgA, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	1.000
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 3

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.526
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 4

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	IgG, any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.119
	Comments
	Method	Barnard's exact test
	Comments

32. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Filamentous Hemagglutinin as Measured by Mucosal IgA Levels
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to filamentous hemagglutinin (FHA) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted FHA-IgA at each and any immunogenicity timepoint (Day 29 or Day 181) was calculated.
Time Frame	Day 29 and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	20 133.3%	67 446.7%	40 800%	40 266.7%
Day 29	20 133.3%	47 313.3%	20 400%	7 46.7%
Day 181	8 53.3%	53 353.3%	20 400%	43 286.7%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.271
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.226
	Comments
	Method	Barnard's exact test
	Comments

33. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Fimbriae 2/3 as Measured by Mucosal IgA Levels
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to fimbriae 2/3 (FIM) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted FIM-IgA at each and any immunogenicity timepoint (Day 29 and Day 181) was calculated.
Time Frame	Day 29 and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	27 180%	80 533.3%	60 1200%	20 133.3%
Day 29	27 180%	53 353.3%	40 800%	7 46.7%
Day 181	8 53.3%	80 533.3%	60 1200%	14 93.3%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.783
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.001
	Comments
	Method	Barnard's exact test
	Comments

34. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Pertactin as Measured by Mucosal IgA Levels
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertactin (PRN) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was computed for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted PRN-IgA at each and any immunogenicity timepoint (Day 29 and Day 181) was calculated.
Time Frame	Day 29 and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	13 86.7%	53 353.3%	80 1600%	20 133.3%
Day 29	13 86.7%	40 266.7%	60 1200%	13 86.7%
Day 181	8 53.3%	47 313.3%	80 1600%	21 140%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.745
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.068
	Comments
	Method	Barnard's exact test
	Comments

35. Secondary Outcome

Title	Percentage of Participants Achieving Seroconversion to Pertussis Toxin as Measured by Mucosal IgA Levels
Description	Nasal aspirate samples were collected from all participants at screening (baseline), Day 29, and Day 181 to measure total mucosal IgA levels via ELISA assay and mucosal IgA levels to pertussis toxin (PT) pertussis antigen via a bead-based assay. Total mucosal IgA levels were reported in µg/mL; antigen-specific IgA results were reported in ELISA units/mL. The titer ratio of antigen-specific IgA to total mucosal IgA was calculated for each participant at each time point, and the fold rise from baseline of this ratio was subsequently calculated for each participant. Seroconversion was defined as at least a 2-fold rise in antigen-specific titer ratios post-baseline compared to baseline titer ratios. The percentage of participants who seroconverted PT-IgA at each immunogenicity timepoint (Day 29 and Day 181) was calculated.
Time Frame	Day 29 and Day 181

Outcome Measure Data

Analysis Population Description

The Immunogenicity Population includes all participants who received the study vaccination and contributed both pre-vaccination samples and either at least one post vaccination sample for humoral immunogenicity testing for which results were reported, or at least one post vaccination nasal sample for which results were reported.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Any Time Point	40 266.7%	53 353.3%	20 400%	53 353.3%
Day 29	13 86.7%	33 220%	0 0%	53 353.3%
Day 181	42 280%	40 266.7%	20 400%	14 93.3%

Statistical Analysis 1

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^7 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	0.585
	Comments
	Method	Barnard's exact test
	Comments

Statistical Analysis 2

Statistical Analysis Overview	Comparison Group Selection	BPZE1 10^9 CFU by VaxINator, Placebo by VaxINator
	Comments	Any time point
	Type of Statistical Test	Superiority
	Comments
Statistical Test of Hypothesis	p-Value	1.000
	Comments
	Method	Barnard's exact test
	Comments

36. Primary Outcome

Title	Number of Participants Experiencing Severe Solicited Systemic Reactogenicity AEs
Description	Solicited systemic reactogenicity events include fever, feverishness, fatigue, malaise, myalgia, arthralgia, headache, and rash/hypersensitivity. They were graded as grade 1 (mild), grade 2 (moderate), and grade 3 (severe). For all symptoms except rash and fever, an event was considered severe if it caused significant interference and prevented daily activity. Severe rash/hypersensitivity events were those that caused generalized urticaria, anaphylaxis, or angioedema or localized urticaria that required medical encounter. Severe fever was a temperature exceeding 38.9°C.
Time Frame	Day 1 through Day 15

Outcome Measure Data

Analysis Population Description

The safety population consists of all participants who received the study vaccine and for whom any data on safety were available.

Arm/Group Title	BPZE1 10^7 CFU by VaxINator	BPZE1 10^9 CFU by VaxINator	BPZE1 10^9 CFU by Syringe	Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.	800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.	800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
Measure Participants	15	15	5	15
Fever	0 0%	0 0%	0 0%	0 0%
Feverishness	0 0%	0 0%	0 0%	0 0%
Fatigue (tiredness)	0 0%	0 0%	0 0%	0 0%
Malaise (general unwell feeling)	0 0%	0 0%	0 0%	0 0%
Myalgia (body aches/muscular pain)	0 0%	0 0%	0 0%	0 0%
Arthralgia (joint pain)	0 0%	0 0%	0 0%	0 0%
Headache	0 0%	0 0%	0 0%	0 0%
Rash/hypersensitivity	0 0%	0 0%	0 0%	0 0%

Adverse Events

Time Frame	Serious adverse events were collected from the time of vaccination through approximately 6 months after vaccination. Solicited Adverse Events were collected from the time of each study vaccination through 14 days after study vaccination. Unsolicited AEs were collected from the time of study vaccination through approximately 28 days after study vaccination. New onset chronic medical conditions and adverse events of special interest were assessed through the follow-up period.
Adverse Event Reporting Description	Reactogenicity assessments included an assessment of solicited adverse events which includes an assessment of mucosal reactions that include: runny nose, stuffy nose/congestion, nasal pain/irritation, epistaxis, sneezing, sinus pressure/pain, sore throat, cough, and shortness of breath, as well as systemic reactions that include fever, chills, fatigue, malaise, myalgia, arthralgia, headache, and hypersensitivity.
Arm/Group Title	BPZE1 10^7 CFU by VaxINator		BPZE1 10^9 CFU by VaxINator		BPZE1 10^9 CFU by Syringe		Placebo by VaxINator
Arm/Group Description	800 microliters (10^7 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.		800 microliters (10^9 CFU) of BPZE1 administered intranasally with the VaxINator device on Day 1.		800 microliters (10^9 CFU) of BPZE1 administered intranasally with a needleless tuberculin syringe on Day 1.		800 microliters of Placebo administered intranasally with the VaxINator device on Day 1.
All Cause Mortality
	BPZE1 10^7 CFU by VaxINator		BPZE1 10^9 CFU by VaxINator		BPZE1 10^9 CFU by Syringe		Placebo by VaxINator
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/15 (0%)		0/15 (0%)		0/5 (0%)		0/15 (0%)
Serious Adverse Events
	BPZE1 10^7 CFU by VaxINator		BPZE1 10^9 CFU by VaxINator		BPZE1 10^9 CFU by Syringe		Placebo by VaxINator
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	0/15 (0%)		0/15 (0%)		0/5 (0%)		0/15 (0%)
Other (Not Including Serious) Adverse Events
	BPZE1 10^7 CFU by VaxINator		BPZE1 10^9 CFU by VaxINator		BPZE1 10^9 CFU by Syringe		Placebo by VaxINator
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	11/15 (73.3%)		14/15 (93.3%)		3/5 (60%)		13/15 (86.7%)
Blood and lymphatic system disorders
Anaemia	0/15 (0%)	0	0/15 (0%)	0	0/5 (0%)	0	1/15 (6.7%)	1
Eye disorders
Blepharitis	0/15 (0%)	0	0/15 (0%)	0	1/5 (20%)	1	0/15 (0%)	0
Gastrointestinal disorders
Swollen tongue	0/15 (0%)	0	0/15 (0%)	0	0/5 (0%)	0	1/15 (6.7%)	1
General disorders
Fatigue	4/15 (26.7%)	4	4/15 (26.7%)	4	2/5 (40%)	2	5/15 (33.3%)	5
Feeling hot	1/15 (6.7%)	1	2/15 (13.3%)	2	0/5 (0%)	0	1/15 (6.7%)	1
Malaise	3/15 (20%)	3	3/15 (20%)	3	1/5 (20%)	1	2/15 (13.3%)	2
Pyrexia	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	0/15 (0%)	0
Infections and infestations
Acute sinusitis	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	0/15 (0%)	0
Cellulitis	0/15 (0%)	0	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Herpes simplex	0/15 (0%)	0	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Pharyngitis	0/15 (0%)	0	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Investigations
Blood creatinine increased	0/15 (0%)	0	0/15 (0%)	0	0/5 (0%)	0	1/15 (6.7%)	1
Haemoglobin decreased	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	2/15 (13.3%)	2
Platelet count increased	1/15 (6.7%)	1	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
White blood cell count increased	0/15 (0%)	0	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Musculoskeletal and connective tissue disorders
Arthralgia	0/15 (0%)	0	3/15 (20%)	3	1/5 (20%)	1	1/15 (6.7%)	1
Myalgia	0/15 (0%)	0	2/15 (13.3%)	2	1/5 (20%)	1	1/15 (6.7%)	1
Synovial cyst	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	0/15 (0%)	0
Nervous system disorders
Headache	5/15 (33.3%)	5	9/15 (60%)	10	2/5 (40%)	2	8/15 (53.3%)	9
Respiratory, thoracic and mediastinal disorders
Cough	6/15 (40%)	6	2/15 (13.3%)	2	2/5 (40%)	2	2/15 (13.3%)	2
Epistaxis	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	1/15 (6.7%)	1
Nasal congestion	8/15 (53.3%)	8	8/15 (53.3%)	8	2/5 (40%)	2	6/15 (40%)	6
Nasal discomfort	1/15 (6.7%)	1	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Oropharyngeal pain	4/15 (26.7%)	4	4/15 (26.7%)	4	2/5 (40%)	2	3/15 (20%)	4
Paranasal sinus discomfort	1/15 (6.7%)	1	4/15 (26.7%)	4	0/5 (0%)	0	2/15 (13.3%)	2
Rhinorrhoea	6/15 (40%)	7	7/15 (46.7%)	7	2/5 (40%)	2	5/15 (33.3%)	6
Sneezing	4/15 (26.7%)	4	5/15 (33.3%)	5	1/5 (20%)	1	3/15 (20%)	3
Wheezing	2/15 (13.3%)	2	1/15 (6.7%)	1	0/5 (0%)	0	0/15 (0%)	0
Skin and subcutaneous tissue disorders
Rash	1/15 (6.7%)	1	0/15 (0%)	0	0/5 (0%)	0	0/15 (0%)	0

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.